MoonLake Immunotherapeutics
MLTX
43 hedge funds and large institutions have $843M invested in MoonLake Immunotherapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 11 closing their positions.
113% more capital invested
Capital invested by funds: $396M → $843M (+$447M)
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
30% more funds holding
Funds holding: 33 → 43 (+10)
3.85% more ownership
Funds ownership: 96.84% → 100.69% (+3.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$28.1M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.9M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$13.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.87M |
| 5 |
JP Morgan Chase
New York
|
+$4.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$10.5M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$10.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.12M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$4M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.15M |
MLTX Hedge Fund Activity: Q1 2023 in Review
43 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2023, worth a combined $843M — up 113% from $396M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MLTX positions and 11 closed out — a net gain of 10 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $28.1M. The largest seller was BlackRock, cutting an estimated $10.5M.
- 43 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2023, up from 33 in Q4 2022.
- Funds reported $843M of MoonLake Immunotherapeutics stock for Q1 2023, up 113% quarter-over-quarter.
- 21 funds opened new MoonLake Immunotherapeutics positions in Q1 2023 and 11 closed out, a net change of +10 holders.
- The largest MoonLake Immunotherapeutics buyer in Q1 2023 was Adage Capital Partners, an estimated $28.1M added.
- The largest MoonLake Immunotherapeutics seller in Q1 2023 was BlackRock, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2023.